😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingProCLAIM SALE

Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide

Published 21/05/2024, 14:36
©  Reuters Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide

Benzinga - by Vandana Singh, Benzinga Editor.

On Tuesday, Eli Lilly And Company (NYSE:LLY) announced that Chinese regulators have approved its diabetes drug tirzepatide.

This approval sets the stage for heightened competition with Novo Nordisk A/S (NYSE:NVO) in the crucial Asian market.

Tirzepatide, known in the U.S. under the brand names Mounjaro for diabetes and Zepbound for weight loss, will now be used in China to treat adults with type 2 diabetes.

Also Read: Weight Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro.

This development comes as Novo Nordisk’s diabetes drug Ozempic, approved in China in 2021, has seen significant sales growth in the region.

Novo Nordisk’s sales for Ozempic in Greater China, which includes Hong Kong and Taiwan, more than doubled to 4.8 billion Danish Krone in 2023.

Both Eli Lilly and Novo Nordisk are racing to increase production in response to the skyrocketing demand for weight-loss drugs.

These treatments, part of a class known as GLP-1 agonists initially developed for diabetes, are anticipated to drive a global market that could reach $100 billion by the end of the decade.

Citing Ping An Securities, Bloomberg noted that in China alone, the market is expected to grow to 14.9 billion yuan ($2 billion) by 2030.

Eli Lilly has not announced the start date for tirzepatide sales in China or the number of doses to be supplied.

Despite this, the drug’s approval is a significant step, potentially paving the way for off-label use for weight loss, similar to how Novo Nordisk’s Ozempic is utilized following its diabetes clearance in China.

Reuters noted that Novo Nordisk is preparing for its weight-loss drug Wegovy to be approved in China this year, with an anticipated limited launch.

Additionally, Eli Lilly is co-developing another obesity drug, mazdutide, with its Chinese partner Innovent Biologics Inc., while several companies are developing biosimilar versions of Ozempic, aiming to enter the market when Novo’s patent expires.

Read Next: Goldman Scrutinizes Hits, Misses, And Growth Trajectory Concerns For Eli Lilly And Its Obesity and Diabetes Drugs.

Price Action: LLY shares are up 2.63% at $803.75 at last check Tuesday.

Photo by Ciara Kimsey via Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.